GB8928811D0 - An activator for damaged neurocytes for the prevention and treatment of disease - Google Patents

An activator for damaged neurocytes for the prevention and treatment of disease

Info

Publication number
GB8928811D0
GB8928811D0 GB898928811A GB8928811A GB8928811D0 GB 8928811 D0 GB8928811 D0 GB 8928811D0 GB 898928811 A GB898928811 A GB 898928811A GB 8928811 A GB8928811 A GB 8928811A GB 8928811 D0 GB8928811 D0 GB 8928811D0
Authority
GB
United Kingdom
Prior art keywords
neurocytes
activator
disease
prevention
damaged
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GB898928811A
Other versions
GB2231263A (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of GB8928811D0 publication Critical patent/GB8928811D0/en
Publication of GB2231263A publication Critical patent/GB2231263A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Microbiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)

Abstract

An activator for damaged neurocytes for the prevention and treatment of disease which contains a neutral protease or a mixture of a neutral protease and one or more other proteases or Pronase. Preferred neutral proteases are produced by microorganisms of the genus Streptomyces, Serratia or Bacillus and are presented as oral or parenteral preparations.
GB8928811A 1989-05-08 1989-12-21 Use of neutral protease as activator for damaged neurocytes Withdrawn GB2231263A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP1114852A JPH02292226A (en) 1989-05-08 1989-05-08 Agent for activating, preventing and treating disordered nerve cell

Publications (2)

Publication Number Publication Date
GB8928811D0 true GB8928811D0 (en) 1990-02-28
GB2231263A GB2231263A (en) 1990-11-14

Family

ID=14648320

Family Applications (1)

Application Number Title Priority Date Filing Date
GB8928811A Withdrawn GB2231263A (en) 1989-05-08 1989-12-21 Use of neutral protease as activator for damaged neurocytes

Country Status (4)

Country Link
JP (1) JPH02292226A (en)
DE (2) DE3941324A1 (en)
FR (1) FR2646605B1 (en)
GB (1) GB2231263A (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005042012A1 (en) 2003-10-29 2005-05-12 Altus Pharmaceuticals Inc. Non-pancreatic proteases for controlling plasma cholecystokinin (cck) concentration and for treating pain
GB2450747A (en) * 2007-07-06 2009-01-07 Univ Sheffield Treatment of sensorineural hearing loss
CN109295041A (en) * 2018-10-10 2019-02-01 宁波希诺亚海洋生物科技有限公司 With active polypeptide of serrapeptase and preparation method thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1064581A (en) * 1964-04-06 1967-04-05 Rorer Inc William H Preparations containing an antitussive and an enzyme
FR5218M (en) * 1965-06-18 1967-07-03
DE1955844A1 (en) * 1969-11-06 1971-05-19 Blendax Werke Schneider Co Preparations for treating inflammation
US3860702A (en) * 1972-07-11 1975-01-14 Schuyler Dev Corp Anti-inflammatory compositions
JPS57128634A (en) * 1981-02-03 1982-08-10 Eisai Co Ltd Elastase-containing compound increasing absorption
JPS5826822A (en) * 1981-08-10 1983-02-17 Kaken Pharmaceut Co Ltd Preventing and pemedy for liver and kidney diseases
JPS58189122A (en) * 1982-04-30 1983-11-04 Kaken Pharmaceut Co Ltd Preventing agent and remedy for disease
EP0133438A1 (en) * 1983-01-21 1985-02-27 Advanced Drug Technology Corporation Enzyme ointment
JPS59225122A (en) * 1983-05-23 1984-12-18 Kaken Pharmaceut Co Ltd Remedy and improver for cancerous cachexia
JPS608227A (en) * 1983-06-28 1985-01-17 Kaken Pharmaceut Co Ltd Antiallergic enhancer
US4844897A (en) * 1985-09-13 1989-07-04 Hiroshi Maeda Anti-tumor protease preparations
JPS62215533A (en) * 1986-03-17 1987-09-22 Shigemi Fujisaki Preventive and remedy for intractable chronic disease
EP0252004A1 (en) * 1986-06-26 1988-01-07 Ciba-Geigy Ag Pharmaceutical compositions for parenteral application
JPS63295515A (en) * 1987-05-26 1988-12-01 Kao Corp Enteric anticoagulant and thrombosis dissolving preparation
CH680285A5 (en) * 1987-10-02 1992-07-31 Ferag Ag

Also Published As

Publication number Publication date
JPH0577655B2 (en) 1993-10-27
DE3941324C2 (en) 1992-06-25
FR2646605A1 (en) 1990-11-09
JPH02292226A (en) 1990-12-03
FR2646605B1 (en) 1992-08-07
GB2231263A (en) 1990-11-14
DE3943649C2 (en) 1992-10-29
DE3941324A1 (en) 1990-11-15

Similar Documents

Publication Publication Date Title
FI964681A0 (en) Lactobacillus strains of human origin, their compositions and their uses
PL336580A1 (en) Fine-molecular compounds useful in treating inflammatory diseases
AU7026794A (en) Phosphonooxymethyl ethers of taxane derivatives
AU5242000A (en) Nematicidal trifluorobutenes
YU15299A (en) Pharmaceutical compositions
EP0960107A4 (en)
IL137093A0 (en) Methods of inactivating bacteria including bacterial spores
AP9400666A0 (en) Benzofuran derivatives.
MX9704030A (en) 2-heterocyclyloxy and thiomethyl-1,2,5-thiadiazolidin-3-one 1,1-dioxides and compositions and method of use thereof.
IL127918A0 (en) Novel amino sugar and related sugar derivatives of indolylopyrrolocarbazoles their use as antitumor agents and pharmaceutical formulations
AU674378B2 (en) Use of 2-amino-6-A-propylamino-4,5,6, 7-tetrahydrobenzothiazole (pramipexol) as an anti-depressantdrug
AU5186799A (en) Peptides of il-2 and derivatives thereof and their use as therapeutic agents
BG104117A (en) Universally applicable blood plasma
NO972391L (en) 2-Substituted 1,2,5-thiadiazolidin-3-one 1,1-dioxides and their preparations and methods
WO2003031585A3 (en) Transmembrane serine protease 25
AU6415994A (en) Substituted caprolactams and derivatives thereof useful for treatment of hiv disease
GB8928811D0 (en) An activator for damaged neurocytes for the prevention and treatment of disease
GB2324091A (en) Metalloproteinase inhibitors
NO180642C (en) Alkalipullulanase and purely isolated culture of Bacillus sp. microorganism that produces this
TR199701298T1 (en) Tetralins.
DK0577745T3 (en) Bis-naphthalimides containing amide and thioamide compounds as anticancer agents.
KR950700988A (en) Microorganisms, preparation methods therefor and uses thereof
DE59409704D1 (en) INSTRUMENT INSERTABLE INTO THE HUMAN BODY
AU3186189A (en) Isolation of 24-R scymnol
ZA876072B (en) Protein protease inhibitors from streptomyces

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)